Background: In oncology research fields, vitamin D has emerged as the most fruitful issue. The previous decade witnessed intensive efforts in connecting vitamin D with risk reduction and progression of various epithelial cancers, especially, breast cancer.
Introduction
Vitamin D is a steroid hormone that affects on every cell in the body. Receptors that respond to vitamin D have been found in almost on all type of the body cell, and this helps to clarify why it is has this strong impact on so many diseases (John et al., 2007) .
In the oncology research field, vitamin D has emerged as the most fruitful issue in the previous decade with effort connecting it with risk reduction and progression in various epithelial cancers especially in breast cancer.
The relationship between vitamin D and its role in cell growth and differentiation was first established in 1981 when Abe and his colleagues (Abe et al., 1981) studied the role of the vitamin D metabolite, 1α, 25-dihydroxyvitamin D 3 , on mouse myeloid cells. Their research determined that vitamin D is involved in the differentiation of bone marrow cells. These new and exciting findings led to researches that investigated the relationship between vitamin D levels and the potenti al impact on cancer.
In this paper, pertinent studies will be reviewed in a way that leads to an exploration of the relationship between vitamin D levels and breast cancer. The relationship between vitamin D levels and breast cancer will be evaluated, posing the question, "Are women with breast cancer who are vitamin D deficient more likely to have disease progression than women with breast cancer who are not vitamin D deficient?" then the review will classify the available evidence using Johns Hopkins Nursing Evidence-Based Practice Model and Guidelines (Newhouse et al., 2007) as in Table 1 , and also the review will identify areas where further research is needed. 
The Relationship Between Vitamin D and Breast Cancer
There are many studies that investigated the relationship between vitamin D levels and breast cancer, with slight variations from study to study. In a study by Yao et al. (2011) , it was found that increased serum levels were associated with decreased risk of breast cancer. Specifically, they found that those with sufficient levels had a 63% reduction in odds of breast cancer. Goodwin et al. (2009) conducted a study on 512 women with early breast cancer diagnosed 1989 to 1996. Vitamin D levels were measured in stored blood. Clinical, pathologic, and dietary data were accessed to examine prognostic effects of vitamin D. It was concluded that those with decreased levels of vitamin D had an increased risk of distant recurrence and death compared to those with sufficient levels. Palmieri et al. (2006) conducted a study to clarify the role of vitamin D in breast cancer progression by comparing the levels of serum vitamin D in patients with early diagnosis and in those with advanced breast cancer. It was found that a relationship between vitamin D levels and breast cancer, though it was not causal; they simply concluded that women with early breast cancer had higher levels than those with advanced disease.
In a study by Ooi et al. (2010) , the only randomized controlled trial studying this relationship; it was found that vitamin D deficiency promotes the growth of human breast cancer cells in nude mice. Another study by Jeong Kim et al. (2011) indicated that vitamin D deficiency correlated with poor outcome for women with breast cancer, this study was conducted in Korea on 310 Korean women treated in Asan Medical Center, to determine the prognostic effects of serum 25-OHD. Expression of estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 (Her2) were measured using tissue microarrays. Peppone et al. (2011) conducted a retrospective study on 224 women diagnosed with stage 0-III breast cancer. It was concluded that the deficiency of vitamin D among women with breast cancer affect the prognosis of breast cancer and affect the patients quality of life. Jacobs et al. (2012) did a prospective cohort study on 3085 as a subject group and 512 as a control group to evaluate the relation between dietary, supplemental, and total vitamin D intake and recurrent breast cancer. Although they stated that Vitamin D intake was not related to breast cancer recurrence overall; they did find a link between vitamin D levels and breast cancer recurrence for premenopausal women. Vol. 7, No. 1; 2015 that the relationship between vitamin D levels and risk of breast cancer was strongest among premenopausal women. Anderson et al. (2010) conducted study on breast cancer cases aged 25-74 years old to evaluate the associations and potential interaction between vitamin D and calcium (from food and supplements) and breast cancer risk. An inverse relationship between vitamin D supplementation and breast cancer risk was concluded.
Conclusion
A comprehensive search of several electronic databases was conducted in PubMed, MEDLINE, CINAHL, In addition, used the web search engine "Google" for abstracts from 1948 to 2012. Key words used included breast cancer, vitamin D, and breast neoplasm. All subheadings were included. To narrow these results, another search was entered with keyword vitamin D. These two searches were then combined and reviewed for appropriateness to the topic, starting with the most recent journal articles and moving backwards chronologically.
The second search was also initiated utilizing the CINAHL data base. Key words included breast cancer and vitamin D. The time frame included 2008 to 2013. Articles were requested from both medical and nursing journals. The third literature search was initiated through the US National Library of Medicine, using Pub Med/ Cochran Collaboration. Key words included vitamin D deficiency related to breast cancer. Appropriate articles were then reviewed, with the latest studies published being chosen. The combined literature search was rewarded with an abundance of articles. To help narrow the findings, articles were excluded according to date, strength of study, and relevance to the research topic.
The rating scale used to rate these studies was the Johns Hopkins Nursing Evidence-Based Practice Model and Guidelines. Several of the individual studies discussed here as it illustrated in Table ( 2) have been graded as IIIB evidence, and as a whole comprise a level IIIB body of evidence. Cases and controls were interviewed in the hospital by centrally trained interviewers, using food frequency questionnaire (FFQ) was used to assess the patients' usual diet in the previous 2 years.
Intake of vitamin D >3.57 μg or 143 IU appeared to have a protective effect against breast cancer.
The inverse association was consistent across strata of menopausal status. Clinic pathologic data were examined to determine the prognostic effects of serum 25-OHD. Expression of estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 (Her2) were measured using tissue microarrays.
Vitamin D deficiency may be associated with poor outcomes in patients with luminal-type breast cancer. Vitamin D deficiency was defined as a 25-OH vitamin D level < 20 ng/ml, insufficiency as 20-31 ng/ml, and sufficiency as ≥32 ng/ml. Bodu miniral density (BMD) was assessed during the period between 3 months before and 6 months following the baseline vitamin D assessment.
Recommended that vitamin D play a significant role in quality of life for women with breast cancer.
IIIB
The studies included in this review utilized various designs, including case-control, case-series, prospective cohort, prospective comparative observational, and randomized controlled trial. Multiple studies used self-report measures to collect data on lifestyle factors such as diet, physical activity, and past medical history. Biophysiological measures were used, including, but not limited to, phlebotomy to measure serum vitamin D levels and analysis of bone structure in mice at a cellular level. Breast cancer status was assessed using a combination of chart reviews, self-reports, and physician reports. With the exception of the study done by Goodwin et al. (2009) , methods were clearly stated throughout the studies included here.
It is evident in current science that sufficient levels of vitamin D are beneficial in the fight against breast cancer, but more researches must be done to improve the capability of healthcare providers to prescribe appropriate doses of vitamin D for their patients. (NCI, 2010) . Conclusive research has not been done that allows for a change in these guidelines for current practice.
Educating patients at provider visits with both verbal and written instruction about proper vitamin D supplementation is essential. Before women are started on vitamin D supplementation, an initial blood test to establish a baseline vitamin D level is recommended. Follow-up lab work must continue until the level is within an acceptable range. Continuing education will help to ensure that women understand the importance of maintaining sufficient vitamin D levels.
One of the review limitations is that the studies do not lend itself to level IA evidence. Thus, definitive conclusions cannot yet be made, resulting in a gap in the overall evidence. Current evidence is lacking in dosages of supplementation, and practice lacks a concrete framework for prescribing an appropriate dose of vitamin D based on a patient's age, risk factors, and other characteristics. Ooi et al. (2010) recommended that further clinical trials would help to investigate the value of correcting vitamin D deficiency in limiting the progression of breast cancer. More specifically, Yao et al. (2011) called for large prospective studies to be done for temporal causality, while Goodwin et al. (2009) recommended that future randomized trials with adequate power be done that target blood levels of vitamin D.
There is agreement amongst many in the medical community that increased levels of vitamin D are important even as research continues to move in the direction of establishing parameters (Ooi, et al. 2010; Palmieri, et al. 2006) . The current environment among both researchers and clinicians is focused on understanding more clearly how vitamin D works metabolically to support and strengthen one's ability to prevent cancer from occurring or to fight against existing breast cancer. The hope is that with further knowledge of this important process, research might be able to more closely determine the proper levels required to maintain and support a healthy, cancer-free life.
